Vaccine for cervical pre-cancer from HPV 16 or 18
Part of Cancer, Infections, Women’s health & pregnancy clinical trials.
This study tests an experimental vaccine (RG002) for women with cervical pre-cancer caused by HPV types 16 or 18. The vaccine is designed to help the body fight the virus and potentially clear the pre-cancerous cells, possibly avoiding more invasive treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 45 (or up to 55 for part B) and have a body mass index of 30 or lower.
- You have a biopsy-confirmed CIN 2 or CIN 3 (precancerous changes) in the cervix within the last 12 weeks.
- You test positive for HPV type 16 or 18 (or both).
- You are not pregnant, breastfeeding, or planning to become pregnant during the study, and you agree to use effective birth control.
- Your liver, kidney, and blood counts are within acceptable limits.
- You have not had treatment for other cancers in the last 2 years, and you haven't had any HPV vaccine as treatment before (regular preventive HPV shots are okay).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new vaccine called PVX4 for women with HPV16-related cervical dysplasia. It aims to see if the vaccine can help clear the high-risk HPV infection and the abnormal cells on the cervix.
This trial tests an experimental vaccine for women who have HPV type 16 but only mild or no precancerous changes (CIN1 or less). The vaccine uses a special device to help your body's immune system fight the virus, which may prevent it from becoming cervical cancer.
This trial tests a new vaccine called RG1-VLP that may help prevent cancers caused by HPV. It is for healthy women who have not had an HPV vaccine before and are willing to follow study procedures.
This trial aims to develop a vaccine that trains your immune system to fight HPV, the virus that causes cervical cancer. By studying your blood, researchers hope to find better ways to prevent the cancer from coming back.
This early-phase study tests a vaccine designed to help your immune system fight HPV16, a type of human papillomavirus linked to abnormal cells in the cervix. You may or may not be living with HIV, and the team will check safety and immune response after giving the vaccine in a specific way.
This trial tests a new vaccine (pBI-11) given with a device that uses mild electric pulses to help the vaccine enter cells. It is for people who have HPV16 or 18 but no high-grade cervical changes.
Hear when a new Cervical Intraepithelial Neoplasia Grade 2/3 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.